OmniAb (OABI) Insider Steven Crouse Buys 20,000 Shares
Multiple corporate insiders reshuffled their holdings on the same day in June.
Reviewed by automated data checks against the source filing. How we make and check alerts
Steven Crouse bought 20,000 shares of OmniAb, Inc. ($OABI) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OABI is up 12.3% after 1 week, up 4.4% after 1 month and up 126.1% to date (from the $2.03 close on Jun 17, 2026).
OABI
OmniAb, Inc.
Key Points
- Steven Crouse acquired 20,000 shares of OmniAb, Inc. on June 17, 2026, at a transaction price of $0.00.
- The transaction took place alongside multiple other executive transactions on the same day, including trades by Steven Love and Philip Gotwals.
- Wall Street analysts maintain a positive outlook on the biotech firm, with Leerink Partners recently raising its price target to $12.00.
Get $OABI trade alerts by text
We text you when insiders, Congress or big funds trade $OABI. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated OmniAb, Inc. alert may contain errors. Disclosures
Steven Crouse acquired 20,000 shares of OmniAb, Inc. (NASDAQ: OABI) on June 17, 2026. The transaction, disclosed in a filing with the Securities and Exchange Commission, shows Crouse added these shares at an acquisition price of $0.00 per share. This transaction was part of a larger series of trades by corporate insiders at the biotechnology company on that same day.
Inside the Busy Day of OmniAb Executive Stock Deals
Steven Crouse's acquisition of 20,000 shares coincided with several other transactions by OmniAb executives. On June 17, 2026, Crouse also sold 20,000 shares. Meanwhile, Steven Love had a busy day, selling 20,000 shares and buying 40,000 shares. Philip Gotwals participated in both sides of the market as well, selling 20,000 shares and buying 20,000 shares. John Higgins also recorded a sale of 20,000 shares on the same date. These transactions represent a substantial realignment of holdings among the company's leadership team.
Where OmniAb Stock Stands
On Friday, OmniAb shares were trading at $2.34. The biotechnology firm has traded within a range of $1.30 to $5.43 over the past year. The company's 50-day moving average is $3.38, and its 200-day moving average is $2.29. With a market value of around $665.89 million, the stock's recent movements happen as the company continues to develop its antibody platform. The stock does not have a meaningful price-to-earnings ratio because the company is currently unprofitable, posting an earnings per share of -$0.36.
Recent Earnings and Financial Performance
OmniAb reported revenue of $38.46 million, reflecting a modest year-over-year revenue growth of 2.4%. The company's net margin stands at -115.1% and its return on equity is -17.0%. These negative margins highlight the high-cost nature of biotech discovery and development before licensing agreements fully scale. The company's next earnings release is scheduled for November 4, 2026.
Analysts Set New Price Targets
Several Wall Street analysts have updated their views on OmniAb. On October 7, 2026, Leerink Partners maintained an Outperform rating and adjusted its price target upward to $12.0 from $10.0. On the same day, StoneX reiterated a Buy rating and increased its target to $6.0 from $4.0. Earlier, on August 17, 2026, HC Wainwright & Co. reiterated its Buy rating with an $11.0 price target. Across five analyst opinions, the stock has a consensus target mean price of $8.4, with a high target of $11.0 and a low target of $5.0.
What OmniAb Does
OmniAb licenses its proprietary antibody discovery technologies to pharmaceutical companies and academic researchers. Its platforms, including OmniRat, OmniChicken, and OmniMouse, use genetically modified animals to generate human-like antibodies for therapeutic development. By licensing these platforms rather than developing its own drugs from scratch, OmniAb aims to secure steady royalty and milestone payments from its partners.
Looking Forward
Investors tracking OmniAb will want to watch the upcoming earnings report on November 4, 2026, to see if revenue growth begins to outpace operating expenses. While insider transactions like those on June 17, 2026, provide a window into executive activity, they represent historical filings and may not reflect current investment strategies or sentiment.
Related Filing Alerts
Source: Steven Crouse's Form 4 filing on $OABI (Jun 17, 2026). Find the original filing: OABI Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts